PRGO — Perrigo Company plc

Summary of Perrigo's Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Core Net Sales: Declined 3.1% year-over-year; Core organic net sales down 3.5%.
• All-in Net Sales: Decreased 3.2%, impacted by category softness and retailer de-stocking.
• Adjusted EPS: Core adjusted EPS at $0.46 (down $0.12 YoY), all-in adjusted EPS at $0.50 (down $0.07 YoY).
• Operating Income: Declined in both Self-Care and Specialty Care segments, with notable growth in Infant Formula (up 23% YoY).
• Cash Flow: Operating cash flow of $83 million; capital expenditures at $14 million; $40 million returned to shareholders via dividends.
• Debt: Total debt reduced to $3.3 billion after applying proceeds from the Dermacosmetics divestiture.

2. Strategic Updates and Business Highlights

• Leadership Transition: Albert Manzone appointed as Interim President and CEO, emphasizing commitment to customer and investor confidence.
• Three-S Plan: Focus on Stabilizing operations, Streamlining the portfolio, and Strengthening future growth capabilities.
  • Stabilization: Improved service levels in the U.S. (up 1,600 bps to 91%) and internationally (up 1,000 bps to 95%).
  • Streamlining: Portfolio simplification and debt reduction through divestitures, including a recent $359 million sale of Dermacosmetics.
  • Strengthening: Enhanced innovation pipeline, with over 55% of projects leveraging shared platforms.
• Market Position: Gained market share in both U.S. and European markets, with a focus on expanding store brand offerings.

3. Forward Guidance and Outlook

• 2026 Outlook: Full-year guidance for Core and all-in net sales, margins, and earnings per share metrics maintained, with expectations weighted towards the second half of the year.
• Growth Drivers: Anticipated improvements in category trends, innovation, and demand generation efforts are expected to contribute to stronger performance in the latter half of 2026.
• Tax Rate Adjustment: Estimated effective tax rate revised from 20% to approximately 18%.

4. Bad News, Challenges, or Points of Concern

• Category Softness: Continued weakness in seasonal categories such as cough, cold, and allergy products, leading to overall volume declines.
• Retailer De-stocking: Contributed approximately 1.8% to the sales decline, particularly impacting European markets.
• Profitability Concerns: Challenges in maintaining profitability in certain segments, particularly Skin Health, due to lower sales volumes and increased promotional investments.
• Consumer Environment: Ongoing uncertainty regarding consumer demand and macroeconomic pressures, especially in Europe.

5. Notable Q&A Insights

• Infant Formula Review: Strategic review progressing well, with potential options including optimization, partnerships, or divestitures.
• E-commerce Growth: Strong growth in e-commerce sales, outpacing brick-and-mortar performance, with a focus on enhancing relationships with online retailers.
• Demand Generation Strategy: Ongoing efforts to enhance marketing and demand generation across all categories, with positive early signs from allergy and other product lines.
• Tariff Reversal Impact: Approximately $10 million benefit from tariff reversals in Q2, alongside a $6 million one-time cost benefit from the CEO transition.

Overall, Perrigo's Q2 2026 results reflect a challenging environment with declining sales metrics, but strategic initiatives and market share gains indicate potential for recovery and growth in the latter half of the year.